X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Elder Pharma with Natco Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs NATCO PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA NATCO PHARMA ELDER PHARMA/
NATCO PHARMA
 
P/E (TTM) x -0.2 23.1 - View Chart
P/BV x 0.1 17.5 0.6% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 ELDER PHARMA   NATCO PHARMA
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
NATCO PHARMA
Mar-14
ELDER PHARMA/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs380877 43.3%   
Low Rs188424 44.4%   
Sales per share (Unadj.) Rs491.2223.4 219.8%  
Earnings per share (Unadj.) Rs-3.231.1 -10.2%  
Cash flow per share (Unadj.) Rs14.440.3 35.8%  
Dividends per share (Unadj.) Rs05.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs376.5219.5 171.5%  
Shares outstanding (eoy) m20.5433.07 62.1%   
Bonus/Rights/Conversions -PA-  
Price / Sales ratio x0.62.9 19.9%   
Avg P/E ratio x-89.320.9 -426.5%  
P/CF ratio (eoy) x19.716.1 122.1%  
Price / Book Value ratio x0.83.0 25.5%  
Dividend payout %016.1 0.0%   
Avg Mkt Cap Rs m5,83321,504 27.1%   
No. of employees `000NANA-   
Total wages/salary Rs m2,1791,128 193.2%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m10,0897,389 136.5%  
Other income Rs m257167 153.6%   
Total revenues Rs m10,3467,556 136.9%   
Gross profit Rs m-7921,793 -44.2%  
Depreciation Rs m361304 118.7%   
Interest Rs m2,756366 752.7%   
Profit before tax Rs m-3,6531,290 -283.2%   
Minority Interest Rs m046 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m3,7130-   
Tax Rs m125309 40.5%   
Profit after tax Rs m-651,027 -6.4%  
Gross profit margin %-7.824.3 -32.3%  
Effective tax rate %-3.423.9 -14.3%   
Net profit margin %-0.613.9 -4.7%  
BALANCE SHEET DATA
Current assets Rs m9,2403,681 251.0%   
Current liabilities Rs m9,9983,123 320.2%   
Net working cap to sales %-7.57.6 -99.3%  
Current ratio x0.91.2 78.4%  
Inventory Days Days4689 51.8%  
Debtors Days Days6059 102.1%  
Net fixed assets Rs m10,1247,685 131.7%   
Share capital Rs m206331 62.2%   
"Free" reserves Rs m5,5826,670 83.7%   
Net worth Rs m7,7347,259 106.5%   
Long term debt Rs m4,889955 512.0%   
Total assets Rs m22,88211,957 191.4%  
Interest coverage x-0.34.5 -7.2%   
Debt to equity ratio x0.60.1 480.6%  
Sales to assets ratio x0.40.6 71.4%   
Return on assets %11.811.7 100.9%  
Return on equity %-0.814.2 -6.0%  
Return on capital %22.320.7 107.6%  
Exports to sales %3.039.4 7.7%   
Imports to sales %0.45.7 7.5%   
Exports (fob) Rs m3072,908 10.5%   
Imports (cif) Rs m43421 10.2%   
Fx inflow Rs m3073,445 8.9%   
Fx outflow Rs m125703 17.8%   
Net fx Rs m1812,743 6.6%   
CASH FLOW
From Operations Rs m11,7541,440 816.1%  
From Investments Rs m-561-1,089 51.5%  
From Financial Activity Rs m-6,762-353 1,917.2%  
Net Cashflow Rs m4,432-1 -297,429.5%  

Share Holding

Indian Promoters % 39.6 52.0 76.1%  
Foreign collaborators % 0.0 1.5 -  
Indian inst/Mut Fund % 7.5 7.8 95.7%  
FIIs % 16.8 16.6 101.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 26.0 138.8%  
Shareholders   16,479 25,395 64.9%  
Pledged promoter(s) holding % 77.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   UNICHEM LAB  AUROBINDO PHARMA  IPCA LABS  GLENMARK PHARMA  SUN PHARMA  

Compare ELDER PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Day Flat; Oil and Gas Stocks Lead Losses(Closing)

After opening the day in red, share markets in India witnessed negative trading activity throughout the day and ended the day on a weak note.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA - DR. REDDYS LAB COMPARISON

COMPARE ELDER PHARMA WITH

MARKET STATS